

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Viventia Biotech Inc.	06/07/2010
RECEIVING PARTY DATA	
Name:	VIVENTIA BIOTECHNOLOGIES INC.
Street Address:	147 Hamelin Street
City:	Winnipeg, MB
State/Country:	CANADA
Postal Code:	R3T 3Z1
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7115722
CORRESPONDENCE DATA	
Fax Number:	4122810717
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	412-454-5000
Email:	docketingpgh@pepperlaw.com
Correspondent Name:	Pepper Hamilton LLP
Address Line 1:	500 Grant Street
Address Line 2:	Suite 5000
Address Line 4:	Pittsburgh, PENNSYLVANIA 15219-2507
ATTORNEY DOCKET NUMBER:	140260.00141
NAME OF SUBMITTER:	N. Nicole Endejann, Reg. No. 50229
Signature:	/N. Nicole Endejann/
Date:	08/27/2013
Total Attachments: 9	

OP \$40.00 7115722

source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page1.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page2.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page3.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page4.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page5.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page6.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page7.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page8.tif
source=Executed_Assignment_ViventiaBiotech_to_ViventiaBiotechnologies#page9.tif

WORLDWIDE

ASSIGNMENT

WHEREAS VIVENTIA BIOTECH INC., whose full post office address is 7895 Tranmere Drive, Suite 204, Mississauga, Ontario, L5S 1V9, Canada (formerly at 5060 Spectrum Way, Suite 405, Mississauga, Ontario, L4W 5N5, Canada) is the applicant/patentee of the patents and patent applications that are listed on Schedule A attached hereto,

AND WHEREAS VIVENTIA BIOTECHNOLOGIES INC. whose full post office address is 7895 Tranmere Drive, Suite 204, Mississauga, Ontario, L5S 1V9, Canada, has acquired from **VIVENTIA BIOTECH INC.** its whole right, title and interest for the United States of America, Canada and all other countries in and to the said invention and in and to any Letters Patent that may be obtained therefore, and in and to said applications,

NOW THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt of all of which is hereby acknowledged, **VIVENTIA BIOTECH INC.** by these presents confirm that it has sold, assigned and transferred and do hereby sell, assign and transfer unto the said **VIVENTIA BIOTECHNOLOGIES INC.** its full and exclusive right to the said invention in the United States of America, Canada and all other countries and its entire right, title and interest in and to any and all Letters Patent which may be granted therefore, and its entire right, title and interest in and to said application, and in and to any divisions, continuations, continuations-in-part, renewals, re-examinations and extensions of said application and to any other patent application and patents that claim priority for the aforementioned patent application, together with its right to claim the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property based on said patents and patent applications.

VIVENTIA BIOTECH INC. agrees that it will without further consideration do all such things and execute all such documents as may be necessary or desirable to obtain and maintain patents for said invention and for additions and modifications thereto in any and all countries, and to vest title thereto in said **VIVENTIA BIOTECHNOLOGIES INC.** its successors, assigns and legal representatives or nominees.


VIVENTIA BIOTECH INC. hereby authorizes and requests the Commissioner of Patents and Trademarks in the U.S. and all other equivalent patent granting authorities in other jurisdictions to issue said Letters Patent to the said **VIVENTIA BIOTECHNOLOGIES INC.**, the assignee of its entire right, title and interest in and to the same, for its sole use and benefit, and for the use and benefit of its successors and assigns, to the full end of the term for which Letters Patent may be granted as fully and entirely as the same would have been held by them had this assignment and sale not been made.


The undersigned hereby grant the firm of Bereskin & Parr LLP/ S.E.N.C.R.L., s.r.l. (Suite 4000, 40 King Street West, Toronto, Ontario M5H 3Y2, Canada) the power to insert on this assignment any further identification which may be necessary in order to comply with the rules of the United States Patent and Trademark Office or other Patent Offices in the world for recordation of this document.

Signed this 7th day of JUNE, 2010, at TORONTO,


ONTARIO, CANADA.

Viventia Biotech Inc.


Witness


Name: Al Grey Dan
Title: President


Witness


Name: Elias Toby
Title: Chief Financial Officer

Assignee Acceptance:

Signed this 30 day of JUNE, 2010, at MISSISSAUGA.

Viventia Biotechnologies Inc.

J.L. Banington
Witness

W. Chapman
Name: WENDY CHAPMAN
Title: CHIEF OPERATING OFFICER

SCHEDULE A

Title: ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS

Country	Filing Date	Application No.	Patent No.	Issue Date	B&P File No.
Europe	May 22, 1997	97929703.3	912738	July 30, 2008	10241-6
Canada	May 22, 1997	2255540	2,255,540	May 15, 2007	10241-15
Israel	May 22, 1997	127193	127193	Feb. 1, 2007	10241-17
Japan	May 22, 1997	9-542853	4124486	May 16, 2008	10241-18
U.S.A.	May 22, 1997	09/194164	7115722	Oct. 3, 2006	10241-25
U.S.A.	May 22, 1997	08/862124	6207153	Mar. 27, 2001	10241-34
New Zealand	May 22, 1997	332566	332566	Dec. 7, 2000	10241-35
New Zealand	May 22, 1997	505305	505305	Oct. 7, 2002	10241-36
Australia	May 22, 1997	72432/00	775448	Feb. 24, 2005	10241-37
U.S.A.	Aug. 29, 2003	10/651453	7166286	Jan. 23, 2007	10241-40
France	May 22, 1997	97929703.3	912738	July 30, 2008	10241-190
Germany	May 22, 1997	97929703.3	912738	July 30, 2008	10241-191
United Kingdom	May 22, 1997	97929703.3	912738	July 30, 2008	10241-196

Title: TUMOR SPECIFIC ANTIBODY

Patent Cooperation Treaty	June 10, 2005	PCT/CA2005/000899			10241-51
Canada	June 10, 2005	2,569,788			10241-91
U.S.A.	June 10, 2005	11/570198			10241-92
Israel	June 10, 2005	179891			10241-93
Japan	June 10, 2005	2007-526144			10241-94

China	June 10, 2005	2005-80027200.5			10241-95
Australia	June 10, 2005	2005252275			10241-97
Europe	June 10, 2005	5754865.3			10241-98
New Zealand	June 10, 2005	552476		Jan. 7, 2010.	10241-99
South Africa	June 10, 2005	200700145			10241-100
India	June 10, 2005	221/DELNP/2007			10241-101
Hong Kong	Feb. 6, 2008	8101438.0			10241-141

Title: CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS

Patent Cooperation Treaty	Dec. 21, 2005	PCT/CA2005/001953			10241-64
China	Dec. 21, 2005	2005 80048522.8			10241-107
Europe	Dec. 21, 2005	5823959.1			10241-108
U.S.A.	Dec. 21, 2005	11/722,420			10241-109
Japan	Dec. 21, 2005	2007-547125			10241-110
India	Dec. 21, 2005	5064/DELNP/2007			10241-112
Canada	Dec. 21, 2005	2,591,768			10241-113
Australia	Dec. 21, 2005	2005318836			10241-114
New Zealand	Dec. 21, 2005	556055		April 8, 2010	10241-115
South Africa	Dec. 21, 2005	2007/05837		May 28, 2008	10241-116
Israel	Dec. 21, 2005	183958			10241-117
Hong Kong	Aug. 28, 2008	81095792			10241-170

Title: HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CELL CYCLE INDEPENDENT GLIOMA SURFACE ANTIGEN

Germany	June 16, 1995	95922373.6	695 22 689.4-08	Sept. 12, 2001	10241-27
United Kingdom	June 16, 1995	95922373.6	766736	Sept. 12, 2001	10241-28
U.S.A.	June 21, 1994	08/264093	5639863	June 17, 1997	10241-30
France	June 16, 1995	95922373.6	766736	Sept. 12, 2001	10241-31

Title: ENDOTOXIN REMOVAL

U.S.A.	Apr. 19, 2007	60/912,705			10241-11
Patent Cooperation Treaty	Apr. 18, 2008	PCT/CA2008/000710			10241-144
Canada	Apr. 18, 2008	2,684,328			10241-204

Title: METHOD AND SYSTEM FOR IDENTIFICATION OF ANTIGEN

U.S.A.	Dec. 21, 2005	60/751,967			10241-67
Patent Cooperation Treaty	Apr. 4, 2006	PCT/CA2006/000514			10241-71
Hong Kong	June 25, 2008	8107063.9			10241-169

Title: METHODS AND PROCESSES FOR CONTROLLING FERMENTATION

U.S.A.	Nov. 7, 2005	60/733,795			10241-63
Patent Cooperation Treaty	Nov. 7, 2006	PCT/CA2006/001819			10241-89
United States	Nov. 7, 2006	12/092,774			10241-146
Canada	Nov. 7, 2006	2,632,457			10241-147
China	Nov. 7, 2006	200680050244.4			10241-150

Title: METHODS FOR GENERATING AND SCREENING FUSION PROTEIN LIBRARIES AND USES THEREOF

U.S.A.	Dec. 23, 2005	60/752,871			10241-65
Patent Cooperation Treaty	Dec. 22, 2006	PCT/CA2006/002113			10241-96
Australia	Dec. 22, 2006	2006329208			10241-161
Canada	Dec. 22, 2006	2,633,138			10241-162
China	Dec. 22, 2006	200680053419.7			10241-163
Europe	Dec. 22, 2006	6840540.6			10241-164
India	Dec. 22, 2006	6153/DELNP/2008			10241-165
Israel	Dec. 22, 2006	192222			10241-166
Japan	Dec. 22, 2006	2008-546061			10241-167
U.S.A.	Dec. 22, 2006	12/097,419			10241-168

Title: NOVEL CANCER-ASSOCIATED ANTIGEN

U.S.A.	Dec. 21, 2005	60/751,965			10241-66
Patent Cooperation Treaty	Dec. 21, 2006	PCT/CA2006/002101			10241-90
Australia	Dec. 21, 2006	2006329198			10241-151
Canada	Dec. 21, 2006	2633131			10241-152
China	Dec. 21, 2006	200680053091.9			10241-153
Europe	Dec. 21, 2006	6840528.1			10241-154
India	Dec. 21, 2006	5549/DELNP/2008			10241-155
Israel	Dec. 21, 2006	192119			10241-156
Japan	Dec. 21, 2006	2008-546058			10241-157
New Zealand	Dec. 21, 2006	569450			10241-158
United States	Dec. 21, 2006	12/097,336			10241-159
Russian Federation	Dec. 21, 2006	2008129770			10241-160

Title: IMMUNOTOXIN FUSIONS COMPRISING AN ANTIBODY FRAGMENT AND A PLANT TOXIN LINKED BY PROTEASE CLEAVABLE LINKERS

U.S.A.	Oct. 30, 2006	60/885132		10241-87
Patent Cooperation Treaty	Oct. 30, 2007.	PCT/CA2007/001927		10241-135
EP	Oct. 30, 2007	7816077.7		10241-201
Canada	Oct. 30, 2007	2,668,017		10241-202
US	Oct. 30, 2007	12/447,748		10241-203

Title: NUCLEOTIDE SEQUENCES OPTIMIZED FOR EXPRESSION OF RECOMBINANT PROTEIN

U.S.A.	Apr. 19, 2007	60/912,732		10241-102
Patent Cooperation Treaty	Apr. 18, 2008	PCT/CA2008/000711		10241-145
Canada	Apr. 18, 2008	2,684,330		10241-205
U.S.A.	Apr. 18, 2008	12/596,188		10241-206

Title: NOVEL CANCER-SPECIFIC ANTIBODY AND CANCER ASSOCIATED ANTIGENS

U.S.A.	Oct. 25, 2007	60/982,575		10241-119
Patent Cooperation Treaty	Oct. 23, 2008	PCT/CA2008/001878		10241-188
Australia	Oct. 23, 2008			10241-213
Canada	Oct. 23, 2008			10241-214
China	Oct. 23, 2008			10241-215
Europe	Oct. 23, 2008			10241-216
Japan	Oct. 23, 2008			10241-217
U.S.A.	Oct. 23, 2008	12/738,885		10241-218

Title: NOVEL CANCER ASSOCIATED ANTIBODY AND ANTIGEN

U.S.A.	Nov. 27, 2007	60/990,494			10241-124
Patent Cooperation Treaty	Nov. 27, 2008	PCT/CA2008/002076			10241-197
Australia	Nov. 27, 2008				10241-219
Canada	Nov. 27, 2008				10241-220
China	Nov. 27, 2008				10241-221
Europe	Nov. 27, 2008				10241-222
Israel	Nov. 27, 2008				10241-223
Japan	Nov. 27, 2008				10241-224
U.S.A.	Nov. 27, 2008	12/744,523			10241-225

Title: NOVEL NUCLEIC ACID SEQUENCES FOR THE EXPRESSION OF RECOMBINANT PROTEINS

U.S.A.	Sept. 27, 2007	60/975,718			10241-126
Patent Cooperation Treaty	Sept. 26, 2008	PCT/CA2008/001680			10241-171
Canada	Sept. 26, 2008				10241-211
U.S.A.	Sept. 26, 2008	12/679,963			10241-212